Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
2.

Burden of disease in children with respiratory tract infections in primary care: diary-based cohort study.

Schot MJC, Dekker ARJ, van Werkhoven CH, van der Velden AW, Cals JWL, Broekhuizen BDL, Hopstaken RM, de Wit NJ, Verheij TJM.

Fam Pract. 2019 Nov 18;36(6):723-729. doi: 10.1093/fampra/cmz024.

PMID:
31166598
3.

Point-of-care C-reactive protein to assist in primary care management of children with suspected non-serious lower respiratory tract infection: a randomised controlled trial.

Schot MJ, Van den Bruel A, Broekhuizen BD, Cals JW, Noteboom EA, Balemans W, Hopstaken RM, van Delft S, de Wit NJ, Verheij TJ.

BJGP Open. 2018 Jul 11;2(3):bjgpopen18X101600. doi: 10.3399/bjgpopen18X101600. eCollection 2018 Oct.

4.

Diagnostic value of signs, symptoms and diagnostic tests for diagnosing pneumonia in ambulant children in developed countries: a systematic review.

Schot MJC, Dekker ARJ, Giorgi WG, Hopstaken RM, de Wit NJ, Verheij TJM, Cals JWL.

NPJ Prim Care Respir Med. 2018 Oct 26;28(1):40. doi: 10.1038/s41533-018-0104-8.

5.

Drug delivery systems and materials for wound healing applications.

Saghazadeh S, Rinoldi C, Schot M, Kashaf SS, Sharifi F, Jalilian E, Nuutila K, Giatsidis G, Mostafalu P, Derakhshandeh H, Yue K, Swieszkowski W, Memic A, Tamayol A, Khademhosseini A.

Adv Drug Deliv Rev. 2018 Mar 1;127:138-166. doi: 10.1016/j.addr.2018.04.008. Epub 2018 Apr 5. Review.

6.

C-reactive protein point-of-care testing in children with cough: qualitative study of GPs' perceptions.

Schot MJ, Broekhuizen BD, Cals JW, Brussee E, de Wit NJ, Verheij TJ, de Groot E.

BJGP Open. 2017 Oct 27;1(4):bjgpopen17X101193. doi: 10.3399/bjgpopen17X101193. eCollection 2018 Jan.

7.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS.

Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10.

PMID:
28335887
8.

Analytical performance, agreement and user-friendliness of six point-of-care testing urine analysers for urinary tract infection in general practice.

Schot MJ, van Delft S, Kooijman-Buiting AM, de Wit NJ, Hopstaken RM.

BMJ Open. 2015 May 18;5(5):e006857. doi: 10.1136/bmjopen-2014-006857.

9.

[Rules and regulations threaten non-pharmacological studies in children].

Schot MJ, Broekhuizen BD, Cals JW.

Ned Tijdschr Geneeskd. 2015;160:A9354. Dutch.

PMID:
26959730
10.

Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, van Tinteren H, Sonke GS, Rutgers EJ, Vrancken Peeters MJ.

Ann Surg. 2015 Feb;261(2):378-82. doi: 10.1097/SLA.0000000000000558.

PMID:
24743607
11.

Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.

Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2014 May;9(2):139-47.

PMID:
24219005
12.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Sonke GS, Mandjes IA, Holtkamp MJ, Schot M, van Werkhoven E, Wesseling J, Vrancken Peeters MJ, Rodenhuis S, Linn SC.

Breast J. 2013 Jul-Aug;19(4):419-26. doi: 10.1111/tbj.12124. Epub 2013 May 20.

PMID:
23682812
13.

Development of children with symptomatic intracranial hemorrhage born after vacuum extraction.

Schot MJ, Halbertsma FJ, Katgert T, Bok LA.

J Child Neurol. 2013 Apr;28(4):520-3. doi: 10.1177/0883073812446162. Epub 2012 Jun 29.

PMID:
22752477
14.

Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial.

Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM.

Ann Fam Med. 2010 Mar-Apr;8(2):124-33. doi: 10.1370/afm.1090.

15.

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.

Straver ME, Aukema TS, Olmos RA, Rutgers EJ, Gilhuijs KG, Schot ME, Vogel WV, Peeters MJ.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1069-76. doi: 10.1007/s00259-009-1343-2. Epub 2010 Feb 4.

16.

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH.

Invest New Drugs. 2010 Apr;28(2):163-70. doi: 10.1007/s10637-009-9244-6. Epub 2009 Apr 30.

PMID:
19404582
17.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JH.

Invest New Drugs. 2007 Jun;25(3):227-35. Epub 2006 Dec 5.

PMID:
17146730
18.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.

Helgason HH, Kruijtzer CM, Huitema AD, Marcus SG, ten Bokkel Huinink WW, Schot ME, Schornagel JH, Beijnen JH, Schellens JH.

Br J Cancer. 2006 Oct 9;95(7):794-800. Epub 2006 Sep 12.

19.

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, Van Zandwijk N, Schellens JH.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3526-33.

20.

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathôt RA, Rosing H, Schot ME, Van Tinteren H, Schellens JH.

Ann Oncol. 2003 Feb;14(2):197-204.

PMID:
12562644
21.

A toxicity identification evaluation of silty marine harbor sediments to characterize persistent and non-persistent constituents.

Stronkhorst J, Schot ME, Dubbeldam MC, Ho KT.

Mar Pollut Bull. 2003 Jan;46(1):56-64.

PMID:
12535970
22.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.

van sen Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, Beijnen JH.

Anticancer Drugs. 2002 Sep;13(8):807-14.

PMID:
12394264
23.

Individual housing during the play period results in changed responses to and consequences of a psychosocial stress situation in rats.

Von Frijtag JC, Schot M, van den Bos R, Spruijt BM.

Dev Psychobiol. 2002 Jul;41(1):58-69.

PMID:
12115291
24.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH.

J Clin Oncol. 2002 Jul 1;20(13):2943-50.

PMID:
12089223
25.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.

Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10. Epub 2002 Jan 22.

PMID:
11935212
26.

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.

Br J Cancer. 2001 Nov 16;85(10):1472-7.

27.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH.

Anticancer Drugs. 2001 Apr;12(4):315-23.

PMID:
11335787
28.

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH.

J Clin Oncol. 2001 Feb 15;19(4):1160-6.

PMID:
11181682
29.

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW.

J Clin Oncol. 1999 Jun;17(6):1906-14.

PMID:
10561232
30.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.

Nannan Panday VR, de Wit R, Schornagel JH, Schot M, Rosing H, Lieverst J, ten Bokkel Huinink WW, Schellens JH, Beijnen JH.

Cancer Chemother Pharmacol. 1999;44(4):349-53.

PMID:
10447584
31.

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

Herben VM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH.

Anticancer Drugs. 1998 Jun;9(5):411-8.

PMID:
9660538

Supplemental Content

Support Center